Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | LTA4H | P09960 | 5/20 | 0.40 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.40 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.40 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.40 |
| ▸ | CYSLTR2 | Q9NS75 | 3/20 | 0.38 |
| ▸ | CYSLTR1 | Q9Y271 | 3/20 | 0.38 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.38 |
| ▸ | MMP13 | P45452 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | FAAH | O00519 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18732228 | 0.85 | BRD4 (0.43) | BRD4LTA4HPDE3BPDE3AP2RY12 | |
| SCHEMBL18732391 | 0.81 | PDE3B (0.41) | BRD4LTA4HPDE3BPDE3AP2RY12 | |
| SCHEMBL18738709 | 0.80 | BRD4 (0.41) | BRD4LTA4HPDE3BPDE3AP2RY12 | |
| SCHEMBL17164338 | 0.79 | MAPT (0.43) | BRD4LTA4HCYSLTR2CYSLTR1PDK2 | |
| SCHEMBL18732229 | 0.75 | BRD4 (0.42) | BRD4LTA4HPDE3BPDE3AP2RY12 | |
| SCHEMBL23811986 | 0.73 | BRD4 (0.36) | BRD4LTA4HPDE3BPDE3AP2RY12 | |
| SCHEMBL4389091 | 0.72 | BRD4 (0.53) | BRD4LTA4HPDE3BPDE3AP2RY12 | |
| SCHEMBL13490815 | 0.70 | BRD4 (0.47) | BRD4LTA4HPDE3BPDE3AP2RY12 | |
| SCHEMBL29198000 | 0.69 | BRD4 (0.51) | BRD4LTA4HPDE3BPDE3AP2RY12 | |
| SCHEMBL15399905 | 0.68 | BRD4 (0.50) | BRD4LTA4HPDE3BPDE3AP2RY12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11691986-B2 | PTEFB inhibiting macrocyclic compounds | BAYER AKTIENGESELLSCHAFT (DE) | 2023-07-04 | — | — | US | disclosed |
| US-11691986-B2 | PTEFB inhibiting macrocyclic compounds | BAYER AKTIENGESELLSCHAFT (DE) | 2023-07-04 | — | — | US | disclosed |
| US-20220281892-A1 | NOVEL PTEFB INHIBITING MACROCYCLIC COMPOUNDS | BAYER AKTIENGESELLSCHAFT (DE) | 2022-09-08 | — | — | US | disclosed |
| US-11254690-B2 | PTEFb inhibiting macrocyclic compounds | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2022-02-22 | — | — | US | disclosed |
| EP-3601253-B1 | NOVEL PTEFB INHIBITING MACROCYCLIC COMPOUNDS | BAYER AG (DE) | 2021-09-15 | — | — | EP | disclosed |
| EP-3359544-B1 | NOVEL MODIFIED MACROCYCLIC COMPOUNDS | Bayer Pharma AG (DE) | 2020-08-12 | — | — | EP | disclosed |
| US-20200123174-A1 | NOVEL PTEFB INHIBITING MACROCYCLIC COMPOUNDS | BAYER AKTIENGESELLSCHAFT (DE) | 2020-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220281892-A1 | NOVEL PTEFB INHIBITING MACROCYCLIC COMPOUNDS | PCLAF, PKD1, RHEB | BRD4 1194/4885LTA4H 1984/4885PDE3B 561/4885 |
| US-11254690-B2 | PTEFb inhibiting macrocyclic compounds | PCLAF, PPIB, RHEB | BRD4 1395/4885LTA4H 2085/4885PDE3B 465/4885 |
| US-20200123174-A1 | NOVEL PTEFB INHIBITING MACROCYCLIC COMPOUNDS | PCLAF, PKD1, RHEB | BRD4 1194/4885LTA4H 1984/4885PDE3B 561/4885 |
| US-11691986-B2 | PTEFB inhibiting macrocyclic compounds | PCLAF, PPIB, RHEB | BRD4 1395/4885LTA4H 2085/4885PDE3B 465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.